Comparing CAR-T Cell Therapies for Multiple Myeloma
Author Information
Author(s): Yang Xu, Wang Feiqing, Yuan Xiaoshuang, Yang Bo, Chen Juan, Cheng Jinyang, Liu Guangyang, Tang Dongxin, Xu Xiao, Wang Sanbin, He Zhixu, Liu Yang, Li Yanju
Primary Institution: Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
Hypothesis
Is GPRC5D CAR-T therapy more effective than BCMA CAR-T therapy in treating relapsed or refractory multiple myeloma?
Conclusion
GPRC5D CAR-T therapy shows enhanced effectiveness compared to BCMA CAR-T therapy in treating patients with relapsed or refractory multiple myeloma.
Supporting Evidence
- GPRC5D CAR-T had a higher overall response rate (ORR) of 89.8% compared to 76.3% for BCMA CAR-T.
- GPRC5D CAR-T showed a complete response rate (CRR) of 50.5%, while BCMA CAR-T had a CRR of 34.3%.
- The relapse rate for GPRC5D CAR-T was significantly lower at 26.0% compared to 57.3% for BCMA CAR-T.
- Both therapies demonstrated acceptable safety profiles with manageable adverse effects.
Takeaway
This study looked at two types of treatments for a blood cancer called multiple myeloma. One treatment worked better than the other, helping more people feel better.
Methodology
A systematic review and meta-analysis of clinical trials comparing BCMA and GPRC5D CAR-T therapies in patients with relapsed or refractory multiple myeloma.
Potential Biases
All studies used a single-arm design, which may introduce bias.
Limitations
Most included studies were early-phase, single-arm trials with varying follow-up durations.
Participant Demographics
Patients with relapsed or refractory multiple myeloma, regardless of age or sex.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI, 72.0%–86.3%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website